4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. The company's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.4SC AG focuses on the development of novel small molecule drugs that can target key indications in cancer through epigenetic mechanisms. The company’s product consists of resminostat, 4SC-202, and 4SC-208.